The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis
Abstract
Purpose: The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Patients and Methods: Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. Results: After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001). Conclusion: These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Self-citation
Cited by
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Self-citationSmeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704
Self-citationUpdate on Survival in Osteosarcoma
Anderson, M. E. (2016) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.08.022 · Cited by 560
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J. S., & Davis, L. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 479
Self-citationGrignani, G., Palmerini, E., Ferraresi, V., D'Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 340
Self-citation
Metadata
- Authors
- Collins, M., Wilhelm, M., Conyers, R., Herschtal, A., Whelan, J., Bielack, S., Kager, L., Kühne, T., Sydes, M., Gelderblom, H., Ferrari, S., Picci, P., Smeland, S., Eriksson, M., Petrilli, A. S., Bleyer, A., & Thomas, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-06-20
- Volume
- 31
- Issue
- 18
- Pages
- 2303-2312
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110022678
- Cited by
- 187
- References
- 1
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. https://app.cochat.ai/papers/10.1200/jco.2012.43.8598
- The paper
- Collins, M., Wilhelm, M., Conyers, R., Herschtal, A., Whelan, J., Bielack, S., Kager, L., Kühne, T., Sydes, M., Gelderblom, H., Ferrari, S., Picci, P., Smeland, S., Eriksson, M., Petrilli, A. S., Bleyer, A., & Thomas, D. M. (2013). Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.8598
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.